Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.
about
Pharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trialsValue of the tuberculin skin testing and of an interferon-gamma release assay in haemodialysis patients after exposure to M. tuberculosis.Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis.Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists.Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.APLAR rheumatoid arthritis treatment recommendations.Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonistsThe first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension studyEfficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn's Disease.Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis.Ramsay hunt syndrome in a patient with rheumatoid arthritis after treatment with infliximab.Rational/antiemotional behaviors in interpersonal relationships and the functional prognosis of patients with rheumatoid arthritis: a Japanese multicenter, longitudinal study.Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study.Pneumocystis jirovecii infection: Cell wall (1→3)-β-D-glucan biology and diagnostic utility.Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.Risk of orthopedic surgical site infections in patients with rheumatoid arthritis treated with antitumor necrosis factor alfa therapy.A systematic review of the influence of anti-TNF on infection rates in patients with rheumatoid arthritis.Rheumatoid arthritis patients fulfilling Korean National Health Insurance reimbursement guidelines for anti-tumor necrosis factor-α treatment and comparison to other guidelines.Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis.Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan.Analysis of C-reactive protein levels and febrile tendency after joint surgery in rheumatoid arthritis patients treated with a perioperative 4-week interruption of tocilizumab.Delayed wound healing and postoperative surgical site infections in patients with rheumatoid arthritis treated with or without biological disease-modifying antirheumatic drugs.Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.Trend of patient characteristics and its impact on the response to adalimumab in patients with rheumatoid arthritis: post hoc time-course analysis of an all-case PMS in Japan.Tuberculosis screening prior to anti-tumor necrosis factor therapy among patients with immune-mediated inflammatory diseases in Japan: a longitudinal study using a large-scale health insurance claims database.Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis.Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients.A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of RheumatoloEfficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study.Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan.Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: Findings from a Phase IIa study
P2860
Q27015772-F0B56563-85CD-4293-A394-C01DA88894D1Q34385468-E3DC9DB5-35CA-4C52-823E-7501D8BB7E37Q34462584-2E8758BA-7BD5-49EA-9CF2-5627E8748FADQ34476049-19C9B363-50B3-4B37-9234-9C6EA9E3586BQ35048301-24027072-4AB9-4D49-97AB-F1AFFA855524Q35762912-33FE1634-4D52-4EB2-B3DD-4180B279C509Q36246140-3F22C069-7B77-43E8-8545-CBBE7F84ECD6Q36475622-D2F98858-F23C-4DEC-A5E8-EE8AA7477CC2Q36513512-0F4909CE-8751-4165-AE24-F35A3B84C8B5Q36761766-06A19561-64DB-40F6-8842-E6102F2EF90DQ37223472-9708C8A7-5A79-47A8-AF6A-673807415E9EQ37288517-45C2309A-D36D-4CAC-A4D8-2D0565176055Q37601987-E8307017-D7E5-4F04-8ADA-999858CB0781Q37616417-F23E3971-09E3-45DC-91F0-C0AA461CAD92Q37699707-4E5EF712-DBB1-48D0-852A-7394812A1C5AQ37790390-807CFC9B-56C9-4E51-887A-D77883C3EC82Q37980484-78B60EBA-D8BF-4739-A9DC-30EB60909EB4Q38002409-54434148-170D-4B3D-9DDF-64C2C9012FB5Q38183297-6BA6B073-8EFB-46D3-BDFF-D9233FBF9E6DQ38581304-829BEBAD-9CEB-475C-BD0C-15DC54C5C9DCQ39258092-32042865-F07D-4E74-9359-774C1FE54229Q40000074-05A3ECB3-5ABD-41F8-B519-40C2C6F169D3Q40349153-52A19F66-93F5-4CF0-8E0E-5B84A072B35FQ40693541-0342D38C-679B-4B95-9E32-544E4195410AQ41109448-EC0A0694-726E-4293-9E57-F36760AEF338Q41610320-550D825C-76E1-4908-A3C0-3BA84E7C9F33Q43366110-A85F8E19-7746-4352-91A8-BAF724CF8C36Q43444262-89BD41E2-C46B-4E79-AC2D-61EC48134BFBQ45098990-CD92C429-0D27-40E0-90FE-B2666D4D637AQ46095754-7CDA027D-307B-4569-B0E4-DB235772EE87Q47602038-D1C0C35B-B486-4B0D-895A-B2B410DEBC7CQ50531047-F65BCA56-E288-4BE9-9126-9ACAAC2A527EQ54268275-8A277EFB-E179-4401-B13E-36D3B22B3634Q54469391-51864053-C265-4E47-B101-A0DA9D674EFDQ58204616-2F7C4E99-F9EE-4F13-BDD8-D7472B89A922
P2860
Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Update on the Japanese guideli ...... rcept in rheumatoid arthritis.
@en
Update on the Japanese guideli ...... rcept in rheumatoid arthritis.
@nl
type
label
Update on the Japanese guideli ...... rcept in rheumatoid arthritis.
@en
Update on the Japanese guideli ...... rcept in rheumatoid arthritis.
@nl
prefLabel
Update on the Japanese guideli ...... rcept in rheumatoid arthritis.
@en
Update on the Japanese guideli ...... rcept in rheumatoid arthritis.
@nl
P2093
P2860
P1433
P1476
Update on the Japanese guideli ...... rcept in rheumatoid arthritis.
@en
P2093
Japan College of Rheumatology
Katsumi Eguchi
Nobuyuki Miyasaka
Ryuji Koike
Tsutomu Takeuchi
P2860
P304
P356
10.3109/S10165-007-0626-3
P577
2007-12-20T00:00:00Z